🇪🇺 PF-06882961 (Cohort 3) in European Union

PF-06882961 (Cohort 3) (pf-06882961-cohort-3) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

PF-06882961 (Cohort 3) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is PF-06882961 (Cohort 3) approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for PF-06882961 (Cohort 3) in European Union?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.